FIELD: chemistry.
SUBSTANCE: described are novel diaminotriazole compounds of general formula
(values of radicals are given in the claim), pharmaceutically acceptable salts thereof, a pharmaceutical composition containing said compounds, a method of inhibiting JAK2 and JAK3 kinase activity and use of the novel compounds to produce a medicinal agent for treating several diseases.
EFFECT: high efficiency of the compounds.
19 cl, 3 tbl, 26 ex
Title | Year | Author | Number |
---|---|---|---|
PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2434871C2 |
TRIAZOLES USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2393155C2 |
AZAINDOLES, USEFUL AS INHIBITORS OF JAK AND OTHER PROTEINKINASES | 2005 |
|
RU2403252C2 |
TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
AZAINDOLES USEFUL AS JANUS KINASE INHIBITORS | 2007 |
|
RU2453548C2 |
HETEROARYL COMPOUNDS AND USING THEM | 2009 |
|
RU2536584C2 |
JAK-INHIBITING TRIAZOLOPYRIDINE COMPOUNDS AND METHODS | 2009 |
|
RU2560153C2 |
PYRAZOLO[1,5-a]PYRIMIDINES, USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2417996C2 |
THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THEM | 2018 |
|
RU2769696C2 |
JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
Authors
Dates
2012-02-27—Published
2005-09-19—Filed